[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Allarity Therapeutics Inc (ALLR)

Allarity Therapeutics Inc (ALLR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,594
  • Shares Outstanding, K 15,911
  • Annual Sales, $ 320 K
  • Annual Income, $ -11,230 K
  • EBIT $ -13 M
  • EBITDA $ -13 M
  • 60-Month Beta 0.56
  • Price/Sales 70.11
  • Price/Cash Flow N/A
  • Price/Book 6.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.25
  • Number of Estimates 1
  • High Estimate $-0.25
  • Low Estimate $-0.25
  • Prior Year $-0.19
  • Growth Rate Est. (year over year) -31.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2300 +18.70%
on 08/03/26
1.5500 -5.81%
on 08/11/26
+0.2500 (+20.66%)
since 07/31/26
3-Month
1.0350 +41.06%
on 07/07/26
1.7291 -15.56%
on 06/04/26
-0.2300 (-13.61%)
since 06/02/26
52-Week
0.7687 +89.93%
on 02/03/26
2.0600 -29.13%
on 09/08/25
-0.1400 (-8.75%)
since 09/02/25

Most Recent Stories

More News
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign

   - Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with...

ALLR : 1.4200 (+4.23%)
Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026

        Principal Investigator Kathleen N. Moore, M.D., a leading expert in advanced ovarian cancer, will present the poster TARPON SPRINGS, Fla., June...

ALLR : 1.4200 (+4.23%)
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast Track designation, in advanced ovarian cancer- Allarity...

ALLR : 1.4200 (+4.23%)
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

         TARPON SPRINGS, Fla., May 8, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage...

ALLR : 1.4200 (+4.23%)
Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Patent expected to be formally granted within three months, subject to standard administrative proceduresPatent would provide exclusivity at least into...

ALLR : 1.4200 (+4.23%)
Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer

         New AACR data highlight stenoparib’s potential in colorectal cancer through WNT pathway modulationThe Stenoparib-DRP® companion diagnostic is...

ALLR : 1.4200 (+4.23%)
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

     Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into...

ALLR : 1.4200 (+4.23%)
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

         Extends Company Cash Runway into Mid-2028Financing Expected to Fund Completion of Phase 2 Ovarian Cancer TrialFinancing Supports Acceleration...

ALLR : 1.4200 (+4.23%)
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need

     Stenoparib is being evaluated in combination with temozolomide clinical benefit in relapsed Small Cell Lung CancerTrial is fully funded by the U.S....

ALLR : 1.4200 (+4.23%)
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment

         This is the first trial combining Allarity’s stenoparib with another anti-cancer agent Stenoparib’s favorable safety profile supports potential...

ALLR : 1.4200 (+4.23%)

Business Summary

Allarity Therapeutics Inc. is a clinical-stage biopharmaceutical company. It involved in developing novel oncology therapeutics together with drug-specific DRP(R) companion diagnostics for personalized cancer care. Allarity Therapeutics Inc. is based in Cambridge, MA U.S.A.

See More

Key Turning Points

3rd Resistance Point 1.5033
2nd Resistance Point 1.4667
1st Resistance Point 1.4433
Last Price 1.4200
1st Support Level 1.3833
2nd Support Level 1.3467
3rd Support Level 1.3233

See More

52-Week High 2.0600
Fibonacci 61.8% 1.5667
Last Price 1.4200
Fibonacci 50% 1.4144
Fibonacci 38.2% 1.2620
52-Week Low 0.7687

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.